Scientific Industries Q2 revenue rises 36% to $1.47 million; gross margin expands 7.5 percentage points to 42.3%

• Scientific Industries posted Q2 revenue of 1,470,400, up 36% year over year.
• Gross margin widened 7.5 percentage points to 42.3% on higher-margin DOTS product line mix in Bioprocessing Systems.
• General and administrative expense fell 25.6% to 553,900 on lower employee-related costs tied to a Bioprocessing Systems reduction in force.
• Selling expense dropped 16.4% to 647,100 on cost-savings moves, including reduced salesforce and marketing activity in Bioprocessing Systems.
• R&D expense rose 2.6% to 694,500 on higher spending for new VIVID pill counter products; other income climbed to 39,000 on higher interest income.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scientific Industries Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001654954-26-007600), on August 14, 2026, and is solely responsible for the information contained therein.